[抗原-免疫抑制剂缀合物对免疫反应的修饰。II. 抗原-免疫抑制剂缀合物的免疫原性]
[Modification of the immune reaction by antigen-immunosuppressive-agent conjugates. II. Immunogenicity of antigen-immunosuppressive-agent conjugates].
作者信息
Drössler K, Fiebig H, Ambrosius H
出版信息
Acta Biol Med Ger. 1976;35(12):1687-97.
The maintenance of specific immunogenicity of carrier proteins is a necessary condition for the successful use of antigen-immunosuppressive agent-conjugates (AIC) for an antigen specific suppression of the immune response. The experimental results indicate that, in spite of the binding of 6-mercaptopurine (6-MP) and toluyl (T) to bovine gamma globulin (BGG) and human serum albumin (HSA), the carrier specific immunogenicity is not significantly altered. The intradermal application of 6-MP-BGG and T-BGG emulsified with complete Freund's adjuvant in guinea pigs results, in all cases, in a well detectable anti BGG hemagglutination and precipitation titer. This kind of immunization leads also to a formation of anti 6-mercaptopurine and anti new antigen determinants (NAD's) antibodies.
载体蛋白特定免疫原性的维持是成功使用抗原-免疫抑制剂缀合物（AIC）进行抗原特异性免疫反应抑制的必要条件。实验结果表明，尽管6-巯基嘌呤（6-MP）和甲苯基（T）与牛γ球蛋白（BGG）和人血清白蛋白（HSA）结合，但载体特异性免疫原性并未显著改变。在豚鼠中皮内注射用完全弗氏佐剂乳化的6-MP-BGG和T-BGG，在所有情况下均能检测到明显的抗BGG血凝和沉淀效价。这种免疫接种还会导致抗6-巯基嘌呤和抗新抗原决定簇（NAD）抗体的形成。
Zotero 插件